Wish to keep on high of the science and politics driving biotech at present? Join to get our biotech e-newsletter in your inbox.
At present, we focus on a lot of authorities maneuvering that impacts biopharma — beginning, after all, with the FDA reinstating Vinay Prasad because the director of CBER. We additionally discuss President Trump’s government order about federal analysis grants, see advocates name for a Vertex probe in South Africa, and extra.
That was quick: Vinay Prasad is again at CBER
Vinay Prasad is returning to guide the biologics division of the FDA simply two weeks after his ouster, which adopted a right-wing marketing campaign criticizing his previous liberal-leaning posts in addition to reported White Home intervention. His reinstatement, confirmed by HHS, comes after FDA Commissioner Marty Makary urged him to contemplate returning, STAT’s Lizzy Lawrence writes.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
